A Cana­di­an start­up re­fu­els to take on a rare car­diac con­di­tion that many pa­tients don't re­al­ize they have

A year and a half ago, a small biotech launched out of Laval, Que­bec to one-up be­ta block­ers for the treat­ment of a rare heart con­di­tion that of­ten goes un­di­ag­nosed. Now, a slate of in­vestors is reach­ing deep­er in­to the pock­ets to dri­ve the com­pa­ny’s push to­ward the clin­ic.

LQT Ther­a­peu­tics un­veiled a $19 mil­lion Se­ries A round on Tues­day to bring its lead com­pound for Long QT syn­drome (LQTS) through Phase I. LQTS is a ge­net­ic dis­or­der that caus­es an elon­ga­tion be­tween the Q and T waves dur­ing a heart­beat, which can lead to rapid, chaot­ic heart­beats or ar­rhyth­mias. Pa­tients with the con­di­tion suf­fer faint­ing spells, seizures, car­diac ar­rest or sud­den death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.